Augmentin for Cellulitis: Dosing and Administration
For uncomplicated cellulitis in adults, Augmentin 875/125 mg twice daily is an appropriate option, though it is not the preferred first-line agent according to IDSA guidelines. 1, 2
Key Clinical Context
The 2014 IDSA guidelines for skin and soft tissue infections clearly outline that beta-lactam antibiotics targeting streptococci and methicillin-susceptible Staphylococcus aureus (MSSA) are the mainstay of cellulitis treatment. While amoxicillin-clavulanate (Augmentin) is listed as an option for impetigo in the IDSA tables, the preferred oral agents for typical cellulitis are cephalexin (500 mg four times daily) or dicloxacillin (500 mg four times daily) in adults 1, 2. These agents provide more targeted coverage without the broader spectrum and added clavulanate that increases gastrointestinal side effects.
When Augmentin Is Appropriate
Augmentin becomes a reasonable choice in specific scenarios:
- Patients with penicillin allergy (non-immediate hypersensitivity type) who cannot tolerate cephalosporins
- Polymicrobial infections or when anaerobic coverage is needed (e.g., cellulitis near the perineum, after animal/human bites)
- Adherence concerns where twice-daily dosing is preferred over four-times-daily regimens
Adult Dosing
Standard dose: Augmentin 875 mg/125 mg orally twice daily 3
- Take at the start of meals to minimize gastrointestinal intolerance and enhance clavulanate absorption 3
- Duration: Typically 5-7 days for uncomplicated cellulitis (though IDSA guidelines don't specify exact duration for Augmentin specifically)
Pediatric Dosing
For children ≥3 months with skin and soft tissue infections:
Standard formulation: 25 mg/kg/day (of amoxicillin component) divided twice daily 1, 2
- Alternative: 25-50 mg/kg/day in 3-4 divided doses for more severe infections
High-dose formulation (Augmentin ES-600): This is specifically indicated for resistant otitis media and sinusitis, not routinely for cellulitis 3. The ES-600 formulation contains different clavulanate ratios and should not be substituted for standard suspensions 3.
Critical Caveats
MRSA Coverage: If MRSA is suspected (purulent drainage, abscess, prior MRSA infection, high local prevalence), Augmentin is inadequate. Add or switch to agents like trimethoprim-sulfamethoxazole, doxycycline, or clindamycin 1, 2
Systemic Toxicity: For patients with SIRS criteria (fever, tachycardia, tachypnea, abnormal WBC), consider parenteral therapy with nafcillin, oxacillin, or cefazolin rather than oral Augmentin 1, 2
Gastrointestinal Effects: Diarrhea occurs in approximately 13-40% of patients due to the clavulanate component 3, 4. The twice-daily formulation has improved tolerability compared to three-times-daily dosing due to lower total daily clavulanate 4
Hepatic Impairment: Dose with caution and monitor liver function regularly 3
Evidence Quality
The IDSA guidelines 1, 2 provide strong recommendations for beta-lactam therapy in cellulitis, though the evidence quality is rated as "low" due to limited high-quality RCTs. Adherence to guideline-concordant therapy (which includes amoxicillin-clavulanate as an acceptable option) has been associated with better outcomes in observational studies 5. However, targeted narrow-spectrum agents like cephalexin remain preferred over Augmentin for typical cellulitis to minimize unnecessary broad-spectrum exposure and side effects 6, 7.
Practical Algorithm
- Assess severity: Systemic toxicity present? → Consider IV therapy
- Evaluate for MRSA risk: Purulent drainage, abscess, or high-risk features? → Add MRSA coverage
- Consider anatomic location: Perianal, post-bite, or polymicrobial concern? → Augmentin appropriate
- Standard cellulitis without above features: Prefer cephalexin or dicloxacillin over Augmentin
- If Augmentin chosen: 875/125 mg twice daily with food for 5-7 days